Making a Pediatric Dose Decision From Sparse PK Samples

From Sparse Concentrations to a Dose Decision

Pediatric dose selection often has to combine two kinds of evidence: a population PK model developed largely from adults, and a small number of concentrations measured in children. The model supplies a structured prediction for a child’s exposure; the sparse samples can then indicate whether that child or age-weight group appears to differ from the prediction. Neither source alone settles the decision. The relevant question is whether the proposed regimen is expected to place exposure in the prespecified target range, with uncertainty made explicit.

The analysis below is hypothetical. It assumes that the adult-informed model’s structural form and covariate relationships are appropriate for the pediatric ages considered, and that the child’s sparse samples are collected and interpreted using the model’s concentration-time predictions. The earlier material on extrapolating adult efficacy and using maturation models provides context for the clinical target and age-dependent clearance; here the focus is the evidence-to-dose calculation when pediatric PK observations are sparse.

State the Model and the Decision Rule

Suppose an adult-informed model predicts clearance as \(CL=4.00(WT/70)^{0.75}M(age)\) L/h, where \(WT\) is weight in kilograms and \(M(age)\) is the model’s age-dependent maturation factor. The model, including its maturation function, is treated as specified from prior work; it is not re-estimated from a handful of pediatric concentrations. For the hypothetical school-age child below, the model gives \(M(age)=1.00\). Assume linear PK over the dose range, steady-state exposure, and known \(F=1\) for the formulation used.

The target range is \(40\) to \(70\) mg·h/L for \(AUC_{24}\). A decision rule should be specified before looking at the individual estimate. In this case, the proposed dose will be considered to meet the exposure criterion if the posterior probability that \(AUC_{24}\) lies within the target range is at least 85%. This criterion is a decision threshold for this hypothetical case, not a universal standard. Other programs may require a different probability threshold or an interval-based criterion, depending on the consequences of under- and overexposure.

Using Sparse Concentrations Without Overinterpreting Them

A concentration is not an AUC. Its interpretation depends on dose history, time since dose, formulation, absorption, and the model’s predicted concentration-time profile. A concentration collected near a peak may inform absorption and distribution differently from one collected late in the interval. Therefore, sparse samples should be evaluated through the model at their actual sampling times, rather than converted directly into an exposure estimate using a single concentration-to-AUC ratio.

For a compact illustration, suppose the model and the child’s sparse samples have been combined to provide a log-scale observation \(y=-0.1687\) for an individual exposure deviation, with standard error \(0.2493\). This is a hypothetical model-based summary of the concentration evidence, not a raw concentration. Let the deviation be \(\delta\), so that the child’s AUC is the population-predicted AUC multiplied by \(\exp(\delta)\). Assume a prior \(\delta\sim N(0,0.25^2)\), and the conditional observation model \(y\mid\delta\sim N(\delta,0.2493^2)\). This normal approximation assumes that the model is adequate at the observed times, the observation error is represented by the stated standard error, and the prior is appropriate for the population’s between-individual variability.

The weighting follows directly by multiplying the prior density by the observation likelihood. Keeping only terms involving \(\delta\), the log of that product is proportional to

Expanding the squares, the coefficient of \(\delta^2\) is \(-\tfrac12(\sigma_0^{-2}+\sigma_y^{-2})\), and the coefficient of \(\delta\) is \(\mu_0\sigma_0^{-2}+y\sigma_y^{-2}\). Completing the square therefore gives the variance and mean above. The observation has greater influence when its variance is smaller, because its precision, \(1/\sigma_y^2\), is larger.

From the Posterior Estimate to the Target-Range Assessment

For the decision calculation, consider a second hypothetical model summary with a population-predicted median \(AUC_{24}\) of 60.8 mg·h/L, and a sparse-data posterior deviation with mean \(-0.0841\) and standard deviation \(0.177\). These values are used together for the following calculation. Since the exposure is the population prediction multiplied by \(\exp(\delta)\), the posterior median exposure is the population median multiplied by \(\exp(\mu_{\mathrm{post}})\). Under a normal posterior for \(\delta\), the corresponding central 90% posterior interval on the log scale is obtained with \(1.645\sigma_{\mathrm{post}}\). This interval describes uncertainty conditional on the stated model, prior, and sparse data; it is not a frequentist confidence interval.

Diagnostics, Alternatives, and Limitations

Sparse-data estimation is useful only when the model and observations support it. Before acting on an estimate, check that the dose, formulation, and administration times are recorded accurately; that samples are linked to the correct dose history and collection times; and that the assay’s quantification limits and error model are appropriate. Compare observed concentrations with model-predicted concentrations at the actual sampling times. A consistent pattern of residuals, such as concentrations repeatedly lower than predicted across children in one age group, may indicate a population-level model misspecification rather than unusual individual clearance.

• Sampling-time ambiguity: a concentration with uncertain time since dose may carry less information than the assumed standard error suggests. Verify timestamps and dosing records.
• Model extrapolation: adult-informed covariate relationships may not adequately represent children at the youngest ages or weights. Check whether the child lies within the model’s supported covariate range and whether maturation is represented appropriately.
• Prior domination: when samples are uninformative, the posterior remains close to the population prediction. That is not evidence that the child has been measured precisely; it is evidence that the data add little information.
• Unmodeled variability: unusually high residual variation, a misspecified absorption profile, or an incorrect formulation assumption can make the reported posterior uncertainty too narrow.
• Decision-rule sensitivity: a probability just above a threshold can change under reasonable alternative priors, model parameters, or target limits. Recalculate under justified alternatives before treating a borderline result as robust.

The main alternatives answer different questions. A population prediction uses covariates but does not incorporate the child’s concentrations; it is useful when no individual data are available. A sparse-data Bayesian or empirical Bayes estimate combines the population model and individual observations, typically shrinking weakly informed individual estimates toward the population. Richer sampling can better characterize the concentration-time profile and reduce reliance on the prior, but requires more blood draws and may still be affected by model assumptions. Noncompartmental exposure estimation generally requires a sufficiently dense concentration-time profile and is not a direct substitute for interpreting one or two samples.

A dose decision should therefore report the model prediction, the contribution and limitations of the sparse data, the exposure uncertainty, the target-range probability, and the decision criterion. The dose is not selected by the posterior median alone: the width of the distribution and the clinical consequences of exposure outside the target range are also relevant. If the model is poorly supported for the child’s age or weight, collecting additional well-timed samples or revising the model may be more defensible than making a finely tuned dose adjustment.